Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT06157151
Title PRGN-2009 in Combination With Pembrolizumab Versus Pembrolizumab in Patients With Recurrent or Metastatic Cervical Cancer
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Precigen, Inc
Indications
Therapies
Age Groups: senior | adult
Covered Countries USA


No variant requirements are available.